Vol 11, No 1 (2017)
Review paper
Published online: 2017-09-20
Page views
487
Article views/downloads
7018
The impact of palliative radiotherapy on quality of life of patients with advanced non-small cell lung cancer
Medycyna Paliatywna w Praktyce 2017;11(1):31-35.
Abstract
In the case of advanced stage of non-small cell lung cancer, patients usually are not suitable for radical oncological treatment given that curative intent and the goal of the treatment is to reduce symptoms and improve quality of life. Patients with thoracic symptoms seem to have worse quality of live. Palliative radiotherapy for patients with incurable non-small cell lung cancer can be used for improving thoracic symptoms and also symptoms from distant metastases. Radiotherapy — in various types of dose fractionation — can improve symptoms as well as quality of lives. It works better in patients with relatively good performance status. Contraindications to palliative radiotherapy include poor performance status, significant weakness and weight loss, and expected short-term survival.
Keywords: non-small cell lung cancerpalliative radiotherapyquality of life
References
- Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4(2): 120–128.
- Jin CJ, Kong W, MacKillop W. Estimating the Need for Palliative Radiation Therapy for Lung Cancer: A Benchmarking Approach. Int J Radiat Oncol Biol Phys. 2017; 98(1): 240–241.
- Kim M, Schrag D, Li L, et al. Predictors of radiation therapy (RT) use among Medicare patients with metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015; 33(29_suppl): 124.
- Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000; 19(2): 137–153.
- LeBlanc TW, Nickolich M, Rushing CN, et al. What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer. 2015; 23(12): 3455–3463.
- Iyer S, Roughley A, Rider A, et al. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014; 22(1): 181–187.
- Mohan A, Singh P, Singh S, et al. Quality of life in lung cancer patients: impact of baseline clinical profile and respiratory status. Eur J Cancer Care (Engl). 2007; 16(3): 268–276.
- Salvo N, Hadi S, Napolskikh J, et al. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol. 2009; 16(2): 16–28.
- Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010; 5(1): 29–33.
- Macbeth FR, Abratt RP, Cho KH, et al. International Atomic Energy Agency. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol. 2007; 82(2): 123–131.
- Rodrigues G, Videtic GMM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011; 1(2): 60–71.
- Report to the Medical Research Council by its Lung Working Party. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer. 1991; 63: 265–270.
- Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015; 1: CD002143.
- Sundstrøm S, Bremnes R, Aasebø U, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004; 22(5): 801–810.
- Senkus-Konefka E, Dziadziuszko R, Bednaruk-Młyński E, et al. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer. 2005; 92(6): 1038–1045.
- Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008; 26(24): 4001–4011.
- Langendijk JA, ten Velde GP, Aaronson NK, et al. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000; 47(1): 149–155.
- Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25(11): 1423–1436.
- Wu JSY, Wong RKS, Lloyd NS, et al. Supportive Care Guidelines Group of Cancer Care Ontario, Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003; 55(3): 594–605.
- Erridge SC, Gaze MN, Price A, et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005; 17(1): 61–67.
- Kramer GW, Wanders SL, Noordijk EdM, et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol. 2005; 23(13): 2962–2970.
- Sundstrøm S, Bremnes RM, Brunsvig P, et al. Norwegian Lung Cancer Study Group. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol. 2006; 1(8): 816–824.
- Bezjak A, Dixon P, Brundage M, et al. Clinical Trials Group of the National Cancer Institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002; 54(3): 719–728.
- Mac Manus MP, Matthews JP, Wada M, et al. Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer. 2006; 106(5): 1110–1116.
- Murray PF, Illsley AL, Bond MG, et al. 115 Audit of high dose palliative radiotherapy survival outcomes in patients with non-small cell lung cancer (NSCLC) in Leeds between 1999 and 2009. Lung Cancer. 2011; 71: S40.
- Lester JF, Macbeth FR, Toy E, et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev. 2006(4): CD002143.
- Stevens W, Stevens G, Kolbe J, et al. Lung cancer in New Zealand: patterns of secondary care and implications for survival. J Thorac Oncol. 2007; 2(6): 481–493.
- Vinod SK, O'Connell DL, Simonella L, et al. Gaps in optimal care for lung cancer. J Thorac Oncol. 2008; 3(8): 871–879.
- Carrato A, Vergnenègre A, Thomas M, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 2014; 30(3): 447–461.
- Ball D, Thursfield V, Irving L, et al. Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study. Lung Cancer. 2013; 82(2): 358–361.
- Brunelli A, Charloux A, Bolliger CT, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34(1): 17–41.
- Giap F, Lau S, Gannavaparu BS, et al. Impact of Baseline Cachexia in Non-Small Cell Lung Cancer on Radiation Therapy Utilization and Survival. International Journal of Radiation Oncology*Biology*Physics. 2016; 96(2): E509.
- Schaafsma J, Coy P. Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000; 47(3): 691–701.
- Falk SJ, Girling DJ, White RJ, et al. Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ. 2002; 325(7362): 465.
- Sundstrøm S, Bremnes R, Brunsvig P, et al. Norwegian Lung Cancer Study Group. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol. 2005; 75(2): 141–148.
- Sloan JA, Zhao X, Novotny PJ, et al. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol. 2012; 30(13): 1498–1504.
- Movsas B, Hu C, Sloan J, et al. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016; 2(3): 359–367.
- Cella D. Quality of life considerations in patients with advanced lung cancer. Semin Oncol. 2004; 31(6 Suppl 11): 16–20.
